美迪西亮相Swiss Biotech 2022

瑞士生物技术日是瑞士领先的生物技术会议。来自欧洲各地生命科学行业的资深专家将参会分享瑞士生物技术成功案例，并设有专题小组进行讨论！

The Swiss Biotech Day is the leading biotechnology conferences in Switzerland.

❖ Meet senior experts from the life science industry from across Europe.

❖ Swiss Biotech Success Stories.

❖ Innovative biotech start-ups and medium-sized biotech companies.

❖ Thematically focused panel discussions.

时间 (Date): May 2-3, 2022

地点 (Location): Basel, Switzerland

展位 (Booth): #13

美迪西国际研发服务部执行副总裁戴学东博士及英国和欧洲业务发展副总裁 Nadine Su女士将展示美迪西一站式药物发现服务，并带来精彩演讲：PROTACs: Make Undruggable Targets Druggable。期待更多美迪西 一站式药物发现服务。演讲时间为：May 3, 13:00-13:15 (GMT+2)。

Medicilon VP of UK and Europe Business Development Ms. Nadine Su in person and Medicilon Executive VP and Head of IDSU, Dr. Xuedong Dai online, are invited to give a presentation to introduce Medicilon fully integrated drug discovery platform and focus on the topic of “PROTACs: Make Undruggable Targets Druggable”.

Dr. Xuedong Dai
Executive VP and Head of IDSU (International Discovery Service Unit) at Medicilon, obtained his Ph.D. in organic chemistry at MIT. He is a senior-level expert with over 20 years of experience focusing on small molecule drug discovery and development in CNS, infectious disease, and oncology therapy areas. He has deep understanding and practical knowledge of drug discovery process, including lead identification, optimization, and development of high quality clinical candidate molecules. Prior to Medicilon, Dr. Dai worked at Janssen, HD Biosciences, GSK, and Xenoport with a demonstrated successful track record of program leadership and made significant contributions to medicinal chemistry programs that led to the marketed drug Horizant®/Regnite® and several other clinical candidates (JNJ-75276617, arbaclofen placarbil, XP21279, and XP23829).

Ms. Nadine Su
20 years’ experience of project management and business development in pharmaceutical and healthcare industries include different sectors, include novel drug research and development, biotechnology application research project management, licensing and new business development in pharmaceutical and healthcare industry in Europe and China. She successfully developed and established the research partnership and business collaboration between EU and China for different novel drug research, novel biotechnology collaboration to achieve over $20M of licensing projects in a year.

美迪西国际研发服务部是美迪西一站式生物医药临床前研发服务平台的重要组成部分，使命是持续助力药企的国际化，向全球药物研发客户提供高质高效高性价比的合成化学、药物设计、以及新药候选化合物服务，以满足客户在临床前新药研究的各个化学领域的研发需求，缩短药物研发的周期，降低药物研发的成本。

美迪西国际研发服务部拥有丰富海外留学工作背景的管理团队和实验人员、世界先进水平的合成实验室、分析实验室、和配套的高端仪器设备。为了给客户提供更优质的服务，国际研发服务部紧跟药物设计以及合成的新进展和新技术，如人工智能/机器学习（AI/ML），蛋白降解靶向嵌合体（PROTAC），高活性药物及抗体药物偶联物（ADC），惰性碳氢键直接官能团化，光致氧化还原反应，以及流动化学等。

The mission of Medicilon International Discovery Service Unit is to provide high quality, efficient and cost-effective synthetic chemistry, drug design, and new drug candidate compound services to global pharmaceutical companies.  We are stride to meet the research and development needs of the clients in various chemical fields of pre-clinical new drug research, shorten the cycle of drug R&D, and reduce the cost of drug R&D.

Medicilon International Discovery Service Unit has a management team and lab personnel with a rich background of studying abroad, a world-leading synthesis and analysis laboratory with installed state-of-the-art instruments and equipment.  In order to provide clients with better services, the International Discovery Service Unit keeps up with new developments and new technologies in drug design and synthesis, such as artificial intelligence/machine learning (AI/ML), proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, and flow chemistry, etc.

美迪西PROTAC药物发现技术平台汇总了当前流行的热门的靶标蛋白配体；建立了广泛的热门靶向蛋白高度亲和力小分子及小分子片段化合物库（TPSM），广泛的E3连接酶，高度亲和力的小分子及小分子片段（E3SM）；建立了linker系统,包括收集大量具有广泛多样性的双官能团连接体（BF-Linker）。这些积累的化合物库可以帮助快速高效的合成大量高活性PROTAC双特异性小分子，极大地提高采用PROTAC技术进行的药物研发过程。除了快速合成之外，我们同时建立和完善的PROTAC生物筛选与测试平台，后续发展到临床前所有阶段。

Medicilon’s PROTAC drug discovery technology platform covers the currently popular target protein ligands. Medicilon has established a linker system with an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, Medicilon can efficiently synthesize a substantial amount of highly active PROTAC bispecific small molecules, which would have the potential to significantly facilitate ithe drug discovery and development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages.

联系我们：

邮箱：marketing@medicilon.com.cn

电话: +86 (21) 5859-1500（总机）